Journal of the American Geriatrics Society
Lauren Gilstrap, Andrea M. Austin, Barbara Gladders, Parag Goyal, A. James O’Malley, Amber Barnato, Anna N.A, Tosteson, Jonathan S. Skinner
Neurohormonal therapy, which includes beta-blockers and angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (ACEi/ARBs), is the cornerstone of heart failure with reduced ejection fraction (HFrEF) treatment. While neurohormonal therapies have demonstrated efficacy in randomized clinical trials, older patients, which now comprise the majority of HFrEF patients, were underrepresented in those original trials. This study aimed to determine the association between short- (30 day) and long-term (1 year) mortality and the use of neurohormonal therapy in HFrEF patients, across the age spectrum.